Therapeutic Cancer Vaccine Articles & Analysis: Older
25 articles found
In the realm of biotechnology and pharmaceuticals, stable cell lines serve as a foundation for producing high-yield protein therapeutics, monoclonal antibodies, and vaccines. They are routinely employed to study gene function, signal transduction pathways, and drug screening processes. ...
Understanding Clonality Analysis Clonality refers to the origin of a cell population from a single 'parent' or progenitor cell through asexual reproduction or division. This concept is vital in cancer studies as it helps track the development of tumor cells from a single mutated cell. Clonality analysis is thus essential in understanding the evolution and the spread of ...
Ribonucleases are also gaining attention in therapeutic development, particularly in the context of RNA-based drugs. Understanding and manipulating RNase activity can enhance the stability and efficacy of RNA therapeutics, including mRNA vaccines. For example, modulating RNase activity can prevent the premature degradation of ...
The development principle of cancer vaccines usually includes the identification of antigens, vaccine formulation, immune activation, and targeting of cancer cells. ...
Pancreatic cancer is one kind of cancer that originates from the pancreas, an important organ behind the stomach. ...
Creative Biogene has established various plant-based protein expression systems to provide recombinant protein production service for global clients. Using our state-of-art platform, we offer a complete service that begins from a specific gene to the purified protein, as well as different options for protein expression systems. We devote to accelerate clients' research in the development and ...
Understanding Clonality Analysis Clonality refers to the origin of a cell population from a single 'parent' or progenitor cell through asexual reproduction or division. This concept is vital in cancer studies as it helps track the development of tumor cells from a single mutated cell. Clonality analysis is thus essential in understanding the evolution and the spread of ...
Bioproduction is a critical element in the creation of many vaccines, therapeutics, and other biopharmaceuticals. A central facet of this process involves the development of stable cell lines that are capable of producing these vital products in abundance and with consistency. This article will explore the in-depth process and importance of stable cell line development in bioproduction. The ...
In the ever-evolving realm of biotechnology, the astonishing advancements in mRNA (messenger RNAs) synthesis are poised to revolutionize various aspects of biological research. This article delineates the eclectic vistas opened up by custom mRNA synthesis services that provide bespoke, high-quality solutions for researchers globally. mRNA synthesis, an integral element of our genetic machinery, ...
Abera’s vaccine delivery platform works as a plug-and-play system where known or novel antigens can be engineered onto our delivery platform to create effective, multivalent vaccines that are cost-effective and fast to produce. We actively work together with academia and industry to enable the use of our vaccine delivery platform in design and development of new vaccines. Many of these ...
Study to be conducted at two leading research institutions in the U.K. Results will inform protocol design of Phase 1/2 clinical trial of Company's lead HSV-2 therapeutic vaccine candidate WOBURN, Mass. and OXFORD, England, Aug. 15, 2022 /PRNewswire/ -- Rational Vaccines, a company focused on revolutionizing the treatment and prevention of herpes to eradicate the disease, today announced the ...
RVx201 Herpes Vaccine Description 2022 RVx201 is a first-in-human herpes simplex virus type 2 (HSV-2) live-attenuated therapeutic vaccine modified to be interferon sensitive that destroys the ability of the virus to inhibit immune responses. Produced by Rational Vaccines, Inc., the technology is based on the pioneering research of the late Dr. William Halford, who dedicated over 25 years to ...
Although vaccines against COVID-19 are unlikely to eradicate the disease in the way that the smallpox vaccine did, they have proved very effective in preventing death and hospitalisation, with enormous societal and economic benefits. There is now considerable research effort invested in building on the success of prophylactic vaccines in ...
The interesting SARS-CoV-2 omicron mutant strain evades immunity mediated by antibodies from vaccination or infection with early mutants due to the accumulation of a large number of spike mutations. Recently, in a research report titled "Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement" published in Science, scientists from institutions such as the University of ...
A breakthrough in nanotechnology accelerates vaccine production While COVID-19 hotspots have continued to emerge driven by the Delta variants, the data still shows that vaccinations are effective at preventing hospitalizations and deaths. While over 4 billion vaccine doses have been administered worldwide, only 27% of the world’s population and only 1.1% of people in low-income countries ...
The designation was awarded for RVx201, a live-attenuated therapeutic vaccine the company is developing for genital herpes resulting from the herpes simplex type 2 (HSV-2) virus. ...
Therapeutic vaccines may well be the next wave of immunotherapy for cancer treatment. Peptide-based vaccines will play a pivotal role in the field. How is a peptide vaccine designed? ...
Closely-held Micron Biomedical is developing a dissolvable microneedle-based technology that could enable self-administration of vaccines and therapeutics. “While microneedle technology is not new, our company represents the evolution of the technology over many years,” Steven Damon, CEO, says in an interview with BioTuesdays.com. “We’re developing an innovative ...
MADISON, Wis.–(BUSINESS WIRE)–An international collaboration of virologists at the University of Wisconsin–Madison and the vaccine companies FluGen and Bharat Biotech has begun the development and testing of a unique vaccine against COVID-19 called CoroFlu. UW–Madison, FluGen, Bharat Biotech to develop CoroFlu, a coronavirus vaccineTweet this CoroFlu will build on the ...
However, these designs are poorly applicable for the development of cancer therapeutic vaccines because the expected safety concerns for these vaccines are not as much as cytotoxic agents. The primary objectives of a cancer therapeutic vaccine phase I trial thus often include ...